ISPARTA BURDUR YÖRESİNDEKİ KOLON KANSERİ HASTALARININ DEMOGRAFİK VE KLİNİK ÖZELLİKLERİ

Öz

Amaç Süleyman Demirel Üniversitesi Tıbbi Onkoloji Polikliniğinde takipli kolon kanseri hastalarının demografik ve klinikopatolojik özelliklerini belirlemek. Gereç ve Yöntem 2010-2021 yılları arasında Süleyman Demirel Üniversitesi Tıp Fakültesi Tıbbi Onkoloji kliniğine başvuran 582 kolon kanseri tanısı almış olan hastanın poliklinik arşiv dosyaları incelendi; yaş, cinsiyet, tümör yerleşim yeri, hastaların ailevi kanser öyküsü, tanı anındaki patolojik TNM evresi kayıt altına alındı. Bulgular Medyan yaş 63,5 ölçüldü. 582 hastanın 375’i (64,4%) erkek, 207’si (35,6) kadındı. Hastaların 34’ünde (%5,8) ailede kolon kanseri öyküsü mevcuttu.147 (%25,3) hastada tümör sağ kolondan, 168 (% 28,9) sol kolondan, 265’inde (%45,5) ise rektumdan kaynaklanmaktaydı. Tanı anında 35’inde(%6) T evresi T1, 61’inde (%10,5) T2, 418’inde (%71,8) T3 ve 67’sinde (%11,5) T4 idi. Hastaların patolojik N evresi 246’sında (%42,3) N0, 168’inde (%28,9) N1, 168’inde (%28,9) N2 idi. TNM derecesine göre evrelendirildiğinde 82 (%14,1) hasta Evre 1, 153 (%26,3) hasta Evre 2, 242 (%41,6) hasta Evre 3, 105 (%18) hasta Evre 4 ‘de tanı almıştır. Hastaların 106’sında (%18,2) tanı anında metastaz saptandı. Sonuç Isparta Burdur yöresinden Süleyman Demirel Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Polikliniğine başvuran hastaların çoğu ileri evrede tanı alan hastalardır. Kolon kanseri taramaları hakkında bölge halkının bilinçlendirilmesi, kolon kanseri farkındalığının arttırılması hayati önem taşımaktadır.

Anahtar Kelimeler

• Kolon Kanseri
• Tarama
• Isparta
• Burdur

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH COLON CANCER IN ISPARTA-BURDUR REGION

Öz

Objective To define the demographic and clinicopathological characteristics of colon cancer patients followed up at Suleyman Demirel University, Medical Oncology Outpatient Clinic. Material and Method Outpatient archive files of 582 patients who applied to Suleyman Demirel University Faculty of Medicine, Medical Oncology Clinic and received a diagnosis of colon cancer between 2010-2021 were examined and patients’ age, gender, tumor location, family history of cancer, and pathological TNM stage at the time of diagnosis were recorded. Results Median age was 63.5 years. Of the 582 patients, 375 (64.4%) were male and 207 (35.6%) were female. Thirty-four (5.8%) of the patients had family history of colon cancer. The origin of the tumor was the right colon in 147 (25.3%) patients, the left colon in 168 (28.9%), and the rectum in 265 (45.5%). At the time of diagnosis, T stage was T1 in 35 (6%) patients, T2 in 61 (10.5%), T3 in 418 (71.8%), and T4 in 67 (11.5%). Pathological N stage was N0 in 246 (42.3%) patients, N1 in 168 (28.9%), and N2 in 168 (28.9%). When staging was made according to TNM grades, 82 (14.1%) patients were diagnosed with Stage 1 disease, 153 (26.3%) with Stage 2 disease, 242 (41.6%) with Stage 3, and 105 (18%) patients were diagnosed with Stage 4 disease. Metastasis was detected at the time of diagnosis in 106 (18.2%) of the patients. Conclusion Most of the patients who apply to Suleyman Demirel University Faculty of Medicine, Medical Oncology Outpatient Clinic from the Isparta-Burdur region are patients diagnosed at an advanced stage. It is of vital importance to raise awareness of colon cancer screenings and increase awareness of colon cancer in the community of this region.

Anahtar Kelimeler

• Colon Cancer
• Screening
• Burdur
• Isparta

Kaynakça

1. 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
2. 2. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359- 69.
3. 3. Moreno CC, Mittal PK, Sullivan PS, Rutherford R, Staley CA, Cardona K, et al. Colorectal cancer initial diagnosis: screening colonoscopy, diagnostic colonoscopy, or emergent surgery, and tumor stage and size at initial presentation. Clinical colorectal cancer. 2016;15(1):67-73.
4. 4. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713-29.
5. 5. Stoffel EM, Murphy CC. Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology. 2020;158(2):341-53.
6. 6. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2017;3(2):211-9.
7. 7. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, et al. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21(23):5294-304.
8. 8. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.

9. 9. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Jama. 2021;325(19):1965-77.
10. 10. Hamilton W, Round A, Sharp D, Peters TJ. Clinical features of colorectal cancer before diagnosis: a population-based case- control study. Br J Cancer. 2005;93(4):399-405.